GW Pharmaceuticals ended 2017 by filing its ... GW specialises in drugs developed from cannabis plants, and already has Sativex (nabiximols) approved in markets including the UK for multiple ...

Purple Day, the international epilepsy awareness day, is today and it encourages people to wear purple and engage in ...

Source: Michael Vi / Shutterstock.com Jazz Pharmaceuticals (NASDAQ:JAZZ) entered the cannabis sector in 2021 when it acquired GW Pharmaceuticals, and it has since established its presence in ...

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing ...

But there have been no FDA-approved medications derived from marijuana—until now ... CEO of manufacturer GW Pharmaceuticals. Next, the company is exploring how effective CBD and other ...

The marijuana index is equally weighted among ... One of the largest companies on the index is the U.K.-based firm GW Pharmaceuticals (GWPH). This company commands a market cap of close to $6 ...

invests in companies from across the entire marijuana industry, including: GW Pharmaceuticals (cannabinoid-focused medicine). Cronos Group (production and distribution). Canopy Growth Corporation ...

After bursting onto the scene several years ago with considerable fanfare, much of the hype about cannabis stocks has quietly died down, and ...

Because extracts are the primary source of cannabis compounds, most companies have focused on improving those sources rather than seeking new ones. For example, GW Pharmaceuticals, the company ...

GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy. But the drug has only just launched and the ...

GW Pharmaceuticals is a cutting-edge UK-based ... and the development of regulatory approved medicines derived from cannabis. GW has established a world leading position in the development of ...